CAMBRIDGE, England—Exonate, an early stage biotechnology company based here, said Monday that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, that will work toward developing an eye drop treatment for retinal vascular diseases, such as Age-Related Macular Degeneration (AMD) and Diabetic Macular Oedema (DMO). The effort will focus on using mRNA targeted therapies. The agreement was facilitated by Johnson & Johnson Innovation. Exonate has developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing, according to the announcement.

Read more